ClinicalTrials.gg
CompletedNCT06989983Updated Jul 4, 2025

A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD5462 and the Absolute Bioavailability of AZD5462

A Phase 1 interventional study of AZD5462 film-coated tablet and [14C]AZD5462 Solution for Infusion in Heart Failure, sponsored by AstraZeneca. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-04.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
30 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 64 studies in Heart Failure by AstraZeneca — 6 open to participants now, 8 under way, 3 of them phase 3. Heart Failure · AstraZeneca.

Enrollment
37th of 39
8 · median 160
Started
2025
with 2 others
Phase 1
13 of 64
none open now
Registered
62nd of 64
by date

Among the 64 studies in Heart Failure by AstraZeneca, this one is the 37th largest by enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2025, is one of 13 in phase 1, and was the 62nd registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.

Browse Heart Failure studies →

Open to participants now

6 of the 64 studies in Heart Failure by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 30 Years to 65 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Heart Failure by AstraZeneca, or all of them as a file.
02

Study summary

A study to investigate how the body breaks down and gets rid of the test medicine, AZD5462.

To help investigate this, the test medicine is radiolabelled, which means that the test medicine has a radioactive component (carbon-14), which helps us to track where the test medicine is in the body. The safety and tolerability of the test medicine will also be studied.

Read the detailed description

This is an open-label, two-period study designed to assess the mass balance recovery, absorption, metabolism, excretion of [14C]AZD5462 and the absolute bioavailability of AZD5462 in healthy male participants.

The study will take place at 1 site in Nottingham, and enrol 8 healthy men aged 30-65 years. The study will include 2 Periods:

  • In Period 1 volunteers will receive a single dose of radiolabelled test medicine as a liquid by mouth.
  • In Period 2 volunteers will receive a single dose of the test medicine as capsules by mouth and shortly afterwards, a very tiny dose of radiolabelled study medicine by injection into a vein.

The participants will be resident in the clinical unit throughout both study periods for a total of 12 nights. The total study duration is approximately up to 6 weeks.

03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • Heart failure
04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males aged 30 to 65 years inclusive
  • in the range 18.0 - 32.0 kg/m2 inclusive and body weight ≥ 50 kg and ≤ 100 kg
  • Regular bowel movements (i.e. average stool production of ≥1 and ≤3 stools per day)

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder
  • History or presence of clinically significant gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs
  • History of severe allergy/ or ongoing allergy/hypersensitivity
  • History of active within 2 years, or under investigation for any form of cancer
  • Participants who do not have suitable veins for multiple venepunctures/cannulation
  • Clinically significant abnormal clinical chemistry, haematology or urinalysis
  • Any clinically significant abnormalities in vital signs
  • Any clinically significant abnormalities on 12-lead
  • Abnormal renal function
  • Radiation exposure exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years, occupationally exposed worker, or have been administered IMP in a radiolabelled ADME study in the last 12 months.
  • Use of any prescribed or non-prescribed medication including antacids, analgesics, herbal remedies, vitamins and minerals
  • Current smokers or known or suspected history of alcohol or drug abuse
  • Excessive intake of caffeine-containing drinks or food
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    AZD5462

    In Period 1, participants will receive one oral dose of \[14C\]AZD5462. In Period 2, participants will receive one oral dose of AZD5462 and one intravenous dose of \[14C\]AZD5462.

    Drug: AZD5462 film-coated tablet · Drug: [14C]AZD5462 Solution for Infusion · Drug: [14C]AZD5462 Oral Solution

Interventions

06

What researchers measure

Primary outcomes

  1. Amount of AZD5462 excreted (Ae) - Period 1

    Mass balance recovery of total radioactivity of \[14C\]AZD5462 in urine and faecal samples

    Time frame: Urine and faecal samples collected from pre-dose until 168 hours post-dose

  2. Amount of AZD5462 excreted expressed as a percentage of the dose administered (Fe) - Period 1

    Mass balance recovery of total radioactivity of \[14C\]AZD5462 in urine and faecal samples

    Time frame: Urine and faecal samples collected from pre-dose until 168 hours post-dose

  3. Cumulative amount of AZD5462 excreted (CumAe) - Period 1

    Mass balance recovery of total radioactivity of \[14C\]AZD5462 in urine and faecal samples

    Time frame: Urine and faecal samples collected from pre-dose until 168 hours post-dose

  4. Cumulative amount of AZD5462 excreted expressed as a percentage of the dose administered (CumFe) - Period 1

    Mass balance recovery of total radioactivity of \[14C\]AZD5462 in urine and faecal samples

    Time frame: Urine and faecal samples collected from pre-dose until 168 hours post-dose

  5. Absolute bioavailability - Period 2

    Absolute bioavailability (F) based on AUC0-inf of oral and IV administration, adjusted for dose

    Time frame: Plasma sample collection from pre-dose to 72 hours post-dose

Secondary outcomes

  1. Time of maximum observed concentration (tmax) for AZD5462 and total radioactivity - Period 1

    PK of AZD5462 and \[14C\]AZD5462 in plasma

    Time frame: Plasma sample collection from pre-dose to 168 hours post-dose

  2. Maximum observed concentration (Cmax) for AZD5462 and total radioactivity - Period 1

    PK of AZD5462 and \[14C\]AZD5462 in plasma

    Time frame: Plasma sample collection from pre-dose to 168 hours post-dose

  3. Area under the curve from time 0 to the time of last measurable concentration (AUC0-t) for AZD5462 and total radioactivity - Period 1

    PK of AZD5462 and \[14C\]AZD5462 in plasma

    Time frame: Plasma sample collection from pre-dose to 168 hours post-dose

  4. Area under the curve from time of the last measurable concentration to infinity as a percentage of the area under the curve extrapolated to infinity (AUC0-extrap) for AZD5462 and total radioactivity - Period 1

    PK of AZD5462 and \[14C\]AZD5462 in plasma

    Time frame: Plasma sample collection from pre-dose to 168 hours post-dose

  5. Terminal elimination half-life (t1/2) for AZD5462 and total radioactivity - Period 1

    PK of AZD5462 and \[14C\]AZD5462 in plasma

    Time frame: Plasma sample collection from pre-dose to 168 hours post-dose

  6. First order rate constant associated with the terminal (log-linear) portion of the curve (λz) for AZD5462 and total radioactivity - Period 1

    PK of AZD5462 and \[14C\]AZD5462 in plasma

    Time frame: Plasma sample collection from pre-dose to 168 hours post-dose

  7. Total body clearance calculated after a single extravascular administration where F (fraction of dose bioavailable) is unknown (CL/F) for AZD5462 and total radioactivity - Period 1

    PK of AZD5462 and \[14C\]AZD5462 in plasma

    Time frame: Plasma sample collection from pre-dose to 168 hours post-dose

  8. Renal clearance calculated using plasma AUC (CLR) for AZD5462 and total radioactivity - Period 1

    PK of AZD5462 and \[14C\]AZD5462 in plasma and urine

    Time frame: Plasma sample collection from pre-dose to 168 hours post-dose

  9. Apparent volume of distribution based on the terminal phase calculated using AUC(0 inf) after a single extravascular administration where F (fraction of dose bioavailable) is unknown (Vz/F) for AZD5462 and total radioactivity - Period 1

    PK of AZD5462 and \[14C\]AZD5462 in plasma and urine

    Time frame: Plasma sample collection from pre-dose to 168 hours post-dose

  10. Area under the curve (AUC) of circulating plasma total radioactivity (TR) or accounting for 10% or more of the dose in excreta - Period 1

    Identification of the chemical structure of each metabolite accounting for more than 10% by AUC of circulating TR or accounting for 10% or more of the dose in urine and faeces

    Time frame: Plasma, urine and faecal samples from pre-dose until 168 hours post-dose

  11. Blood:plasma concentration ratios - Period 1

    Blood:plasma concentration ratios of total radioactivity

    Time frame: Whole blood samples and plasma samples collected from pre-dose until 168 hours post-dose

  12. Amount of unchanged AZD5462 excreted in urine (Ae) - Period 2

    Recovery of total radioactivity of \[14C\]AZD5462 in urine

    Time frame: Urine sample collection from pre-dose to 72 hours post-dose

  13. Amount of unchanged AZD5462 excreted in urine expressed as a percentage of the radioactive dose administered (Fe) - Period 2

    Recovery of total radioactivity of \[14C\]AZD5462 in urine

    Time frame: Urine sample collection from pre-dose to 72 hours post-dose

  14. Cumulative amount of unchanged AZD5462 excreted in urine (CumAe) - Period 2

    Recovery of total radioactivity of \[14C\]AZD5462 in urine

    Time frame: Urine sample collection from pre-dose to 72 hours post-dose

  15. Cumulative amount of unchanged AZD5462 excreted in urine expressed as a percentage of the radioactive dose administered (CumFe) - Period 2

    Recovery of total radioactivity of \[14C\]AZD5462 in urine

    Time frame: Urine sample collection from pre-dose to 72 hours post-dose

  16. Area under the curve from time 0 extrapolated to infinity (AUC0-inf) for AZD5462 and total radioactivity - Period 1

    PK of AZD5462 and \[14C\]AZD5462 in plasma

    Time frame: Plasma sample collection from pre-dose to 168 hours post-dose

  17. Time of maximum observed concentration (tmax) for AZD5462 and [14C]AZD5462 - Period 2

    PK of AZD5462 and \[14C\]AZD5462 in plasma

    Time frame: Plasma sample collection from pre-dose to 72 hours post-dose

  18. Maximum observed concentration (Cmax) for AZD5462 and [14C]AZD5462 - Period 2

    PK of AZD5462 and \[14C\]AZD5462 in plasma

    Time frame: Plasma sample collection from pre-dose to 72 hours post-dose

  19. Area under the curve from time 0 extrapolated to infinity (AUC0-inf) for AZD5462 and [14C]AZD5462 - Period 2

    PK of AZD5462 and \[14C\]AZD5462 in plasma

    Time frame: Plasma sample collection from pre-dose to 72 hours post-dose

  20. Area under the curve from time 0 to the time of last measurable concentration (AUC0-t) for AZD5462 and [14C]AZD5462 - Period 2

    PK of AZD5462 and \[14C\]AZD5462 in plasma

    Time frame: Plasma sample collection from pre-dose to 72 hours post-dose

  21. Area under the curve from time of the last measurable concentration to infinity as a percentage of the area under the curve extrapolated to infinity (AUC0-extrap) for AZD5462 and [14C]AZD5462- Period 2

    PK of AZD5462 and \[14C\]AZD5462 in plasma

    Time frame: Plasma sample collection from pre-dose to 72 hours post-dose

  22. Terminal elimination half-life (t1/2) for AZD5462 and [14C]AZD5462 - Period 2

    PK of AZD5462 and \[14C\]AZD5462 in plasma

    Time frame: Plasma sample collection from pre-dose to 72 hours post-dose

  23. First order rate constant associated with the terminal (log-linear) portion of the curve (λz) for AZD5462 and [14C]AZD5462 - Period 2

    PK of AZD5462 and \[14C\]AZD5462 in plasma

    Time frame: Plasma sample collection from pre-dose to 72 hours post-dose

  24. Total body clearance calculated after a single IV administration (CL) for AZD5462 and [14C]AZD5462 - Period 2

    PK of AZD5462 and \[14C\]AZD5462 in plasma

    Time frame: Plasma sample collection from pre-dose to 72 hours post-dose

  25. Total body clearance calculated after a single extravascular administration where F (fraction of dose bioavailable) is unknown (CL/F) for AZD5462 and [14C]AZD5462 - Period 2

    PK of AZD5462 and \[14C\]AZD5462 in plasma

    Time frame: Plasma sample collection from pre-dose to 72 hours post-dose

  26. Volume of distribution based on the terminal phase calculated using AUC(0-inf) after a single IV administration (Vz) for AZD5462 and [14C]AZD5462 - Period 2

    PK of AZD5462 and \[14C\]AZD5462 in plasma

    Time frame: Plasma sample collection from pre-dose to 72 hours post-dose

  27. Apparent volume of distribution at steady state after a single IV administration (Vss) for AZD5462 and [14C]AZD5462 - Period 2

    PK of AZD5462 and \[14C\]AZD5462 in plasma

    Time frame: Plasma sample collection from pre-dose to 72 hours post-dose

  28. Apparent volume of distribution based on the terminal phase calculated using AUC(0 inf) after a single extravascular administration where F (fraction of dose bioavailable) is unknown (Vz/F) for AZD5462 and [14C]AZD5462 - Period 2

    PK of AZD5462 and \[14C\]AZD5462 in plasma

    Time frame: Plasma sample collection from pre-dose to 72 hours post-dose

  29. Number of subjects with treatment-related adverse events - Periods 1 and 2

    To provide additional safety and tolerability information for AZD5462

    Time frame: Through study duration, an average of 7 weeks

07

Study locations

1 site
  • Research Site
    Ruddington, NG11 6JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual participant-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Jun 2025, 1 month.

Of 77 industry-sponsored phase 1 interventional studies under Heart Failure, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 16. This study's 1 month is below that.

Counting every sponsor, half of 131 studies reached it within 14 months; a quarter within 4 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2025
First posted
May 25, 2025
StartActual
May 20, 2025
Primary completionActual
Jun 25, 2025
CompletionActual
Jun 25, 2025
Last update
Jul 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06989983
Lead sponsor
AstraZeneca
Collaborators
Quotient Sciences
Responsible party
Sponsor
First posted
May 25, 2025
Start date
May 20, 2025
Primary completion
Jun 25, 2025
Completion
Jun 25, 2025
Last update
Jul 4, 2025

Study contacts

Philip Evans, MBChB, MRCS (Ed)
principal investigator · Quotient Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pexerelgon

Start the discussion